Business
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing clinical studies evaluating tegoprubart in kidney transplantation, IgA
About this update from Eledon Pharmaceuticals, Inc.
[{"type":"text","content":"Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing clinical studies evaluating tegoprubart in kidney transplantation, IgA nephropathy, and islet cell transplantation with initial readouts anticipated in late 2022 Cash balance of $84.8M, sufficient to fund operations into 2024 Conference call today at 4:30 PM ET IRVINE, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today reported its fourth quarter and full-year 2021 operating and financial results. “In 2021, our first full year following the acquisition of the rights to tegoprubart, we fully enrolled our ALS trial, initiated several other pre-clinical and clinical trials across four programs, and created momentum heading into 2022,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “We now enter a pivotal year for Eledon, and we look forward to sharing results beginning with topline readout from our Phase 2a study in ALS in the second quarter, followed by initial clinical readouts in our other tegoprubart programs anticipated by year-end.” Fourth Quarter 2021 and Recent Corporate Developments Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart in Amyotrophic Lateral Sclerosis (ALS).Received regulatory clearance to initiate a Phase 1b clinical trial in the United Kingdom in addition to Canada, evaluating tegoprubart as a replacement for tacrolimus as an immunosuppressive regimen component in patients undergoing kidney transplantation.Received regulatory clearance to initiate a Phase 2a clinical trial in Australia, New Zealand and Malaysia, evaluating tegoprubart for the treatment of IgA Nephropathy, with plans to expand the study in up to eight additional countries in 2022.Obtained FDA clearance to initiate a Phase 2a U.S. clinical trial in islet cell transplantation utilizing tegoprubart to prevent allograft rejection for the treatment of Type 1 diabetes.Presented pre-clinical data showing the effectiveness of tegoprubart in preventing islet cell allograft rejection resulting in improved metabolic control in a nonhuman primate mod...